Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Change in Accured Expenses (2021 - 2025)

Kezar Life Sciences' Change in Accured Expenses history spans 5 years, with the latest figure at -$426000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 128.42% year-over-year to -$426000.0; the TTM value through Sep 2025 reached -$8.3 million, down 1178.86%, while the annual FY2024 figure was -$3.1 million, 149.57% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$426000.0 at Kezar Life Sciences, up from -$2.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q3 2023 and bottomed at -$3.6 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $200000.0 (2022), against an average of -$27157.9.
  • The largest annual shift saw Change in Accured Expenses soared 379.5% in 2023 before it tumbled 2709.28% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $60000.0 in 2021, then surged by 233.33% to $200000.0 in 2022, then skyrocketed by 379.5% to $959000.0 in 2023, then crashed by 260.48% to -$1.5 million in 2024, then skyrocketed by 72.32% to -$426000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Change in Accured Expenses are -$426000.0 (Q3 2025), -$2.7 million (Q2 2025), and -$3.6 million (Q1 2025).